Triapine

Triapine is a synthetic, small molecule inhibitor of ribonucleotide reductase with potential anticancer activity. It is a member of the thiosemicarbazone family and is known for its role in cancer treatment.

Chemistry[edit | edit source]

Triapine is a derivative of thiosemicarbazone, a class of compounds known for their anticancer properties. It is a small molecule with a molecular weight of 195.21 g/mol. Its chemical formula is C7H7N3S.

Mechanism of Action[edit | edit source]

Triapine inhibits the M2 subunit of ribonucleotide reductase, an enzyme necessary for DNA synthesis and repair. By inhibiting this enzyme, Triapine prevents the conversion of ribonucleotides into deoxyribonucleotides, which are the building blocks of DNA. This inhibition disrupts DNA synthesis and repair, leading to cell death and potential tumor regression.

Clinical Use[edit | edit source]

Triapine has been studied in clinical trials for the treatment of various types of cancer, including leukemia, non-small cell lung cancer, and cervical cancer. It is typically administered intravenously and is often used in combination with other anticancer drugs to enhance their effectiveness.

Side Effects[edit | edit source]

Like many anticancer drugs, Triapine can cause side effects. These may include nausea, vomiting, fatigue, and myelosuppression. Myelosuppression, a decrease in the production of blood cells, is a particularly serious side effect that can lead to anemia, infections, and bleeding.

Research[edit | edit source]

Research into the use of Triapine for cancer treatment is ongoing. Current studies are investigating its use in combination with other drugs, its effectiveness against different types of cancer, and ways to mitigate its side effects.